Here are relevant reports on : herbal-medicine-market
-
Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028
The global pharmacogenomics market, valued at US$3.3 billion in 2022, stood at US$3.5 billion in 2023 and is projected to advance at a resilient CAGR of 10.6% from 2023 to 2028, culminating in a forecasted valuation of US$5.8 billion by the end of the period. The increasing focus on the translational approach to optimize drug development processes, increasing collaborations and partnerships between key players and research institutes, and rising incidence of cancer are the major driving factors of the pharmacogenomics market.
- Published: February 2024
- Price: $ 4950
- TOC Available:
-
Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization [Array-based, Standard]), Application (Cancer, Personalized Medicine) - Global Forecast to 2030
The global molecular cytogenetics market, valued at US$0.97 billion in 2024, stood at US$1.02 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2030, culminating in a forecasted valuation of US$1.43 billion by the end of the period. The market growth is fueled by increasing incidence of cancer & genetic disorders and rising usage of molecular cytogenetics in clinical pathology testing.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Human Organoids Market by Product (Liver, Kidney, Pancreatic Models (2D, 3D)), Disease Area (Oncology, GI, Neurological Disorders), Application (Drug Toxicity, Personalized Medicine), End User (Pharma & Biotech Companies, CROs) - Global Forecast to 2029
The global human organoids market, valued at US$1.07 billion in 2023, stood at US$1.19 billion in 2024 and is projected to advance at a resilient CAGR of 14.4% from 2024 to 2029, culminating in a forecasted valuation of US$2.33 billion by the end of the period. The main factor driving this market is the rising demand for organoids in drug testing, as they provide more reliable results than conventional 2D cell cultures.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
North American Nuclear Medicine Market / Radiopharmaceuticals Market Size by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) & Region - Global Forecast to 2024
North american nuclear medicine market growth is primed to transition from $2.2 billion in 2019 to $2.7 billion by 2024, showcasing a strong CAGR of 4.1%. Growth in the market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer & cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.
- Published: January 2020
- Price: $ 4950
- TOC Available:
-
Europe Nuclear Medicine Market by Type (SPECT [Tc99m, I-123], PET [F-18, Rb-82], Alpha Emitters, Beta Emitters [Y-90, I-131], Brachytherapy), Application (Onco, Cardio), Procedure, End User (Imaging Center, Hospital) - Forecast to 2030
The Europe nuclear medicine market, valued at USD 2.14 billion in 2024, stood at USD 2.47 billion in 2025 and is projected to advance at a resilient CAGR of 15.8% from 2025 to 2030, culminating in a forecasted valuation of USD 5.15 billion by the end of the period. This growth is driven by the rising application of radiopharmaceuticals and radioisotopes for diagnostic imaging and targeted radionuclide therapies, especially in oncology, cardiology, and neurology. The major drivers of the demand include rising cancer incidence, the aging population, and the high adoption of the PET and SPECT procedures in key European nations.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Clinical Analytics Market by Offering (Raw Data, Platform), Source (EHR, Trials, Claims, RWE), Use Case (CDSS, RPM, PHM, R&D, Pharmacovigilance, Precision Medicine, Regulatory), End User (Hospital, Payer, Pharma, Medtech), Region - Global Forecast to 2030
The global clinical analytics market, valued at US$27.65 billion in 2024, stood at US$33.09 billion in 2025 and is projected to advance at a resilient CAGR of 19.7% from 2024 to 2030, culminating in a forecasted valuation of US$81.32 billion by the end of the period.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Nuclear Medicine Equipment Market by Product (Imaging: PET, SPECT, Gamma; GM Counter, Dose Calibrator), Software (Image Management, PACS, Treatment, Analytic, Workflow), Therapy (Onco, Cardio, Neuro, Ortho), End User & Region - Global Forecasts to 2030
The global nuclear medicine equipment market, valued at US$6.33 billion in 2024, stood at US$6.63 billion in 2025 and is projected to advance at a resilient CAGR of 4.62% from 2025 to 2030, culminating in a forecasted valuation of US$8.31 billion by the end of the period.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
AI in Oncology Market by Player Type (Integrated Suite), Application (Drug Discovery, De Novo Drug Design, Diagnosis, Precision Medicine, Genomic), Technology (CNN, NLP), Cancer Type (Lung), End User (Hospitals, Pharma), & Region - Global Forecast to 2030
The global AI in oncology market, valued at US$1.92 billion in 2023, stood at US$2.45 billion in 2024 and is projected to advance at a resilient CAGR of 29.4% from 2024 to 2030, culminating in a forecasted valuation of US$11.52 billion by the end of the period. The AI in oncology market is experiencing significant growth due to rising investments in the pharmaceutical and biotech companies to develop potential and advance cancer drugs to reduce the growing cancer burden worldwide.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Asia Pacific Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18, Rb-82], Alpha Emitters, Beta Emitters [Y-90], Brachytherapy), Application (Onco, Thyroid, Cardio), Procedure, End User (Imaging Center, Hospital) - Forecast to 2030
The Asia Pacific nuclear medicine market, valued at USD 1.82 billion in 2024, stood at USD 2.13 billion in 2025 and is projected to advance at a resilient CAGR of 17.1% from 2025 to 2030, culminating in a forecasted valuation of USD 4.68 billion by the end of the period.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
US Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18], Alpha Emitters, Beta Emitters [Y-90, Lu-177]), Application (Onco, Neuro), Procedure, End User (Imaging Center, Hospital), Radioisotope, Market Share, Growth - Forecast to 2030
The US Nuclear Medicine market, valued at USD 4.19 billion in 2024, stood at USD 4.81 billion in 2025 and is projected to advance at a resilient CAGR of 14.7% from 2025 to 2030, culminating in a forecasted valuation of USD 9.56 billion by the end of the period. This growth is attributed to the rapid expansion of theranostics and radioligand therapies, growing FDA approval of novel radiopharmaceuticals, and active clinical research at the US hospitals and academic medical centers.
- Published: April 2026
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
